Revenue: As of FY2026 Q1, the actual value is USD 19.47 M.EPS: As of FY2026 Q1, the actual value is USD -1.39.EBIT: As of FY2026 Q1, the actual value is USD -74.97 M.<h3>Financial Performance for Continuing Operations (Three Months Ended March 31, 2026 vs. 2025)</h3><h4>Segment Revenue</h4><ul><li>Total Revenue: Ginkgo Bioworks Holdings, Inc. reported total revenue of $19.5 million for the three months ended March 31, 2026, a decrease of $18.8 million compared to $38.2 million for the same period in 2025 . This decline was primarily attributed to the recognition of $7.5 million in non-cash revenue from a terminated BiomEdit, Inc. contract in the first quarter of 2025 and a reduced scope of services for a major agriculture industry customer . Non-cash revenue decreased from $8.7 million in 2025 to $0.5 million in 2026 .</li><li>Revenue by Industry (2026 vs. 2025):<ul><li>Pharmaceutical and biotechnology: 38% (2026) vs. 31% (2025) </li><li>Government and defense: 35% (2026) vs. 16% (2025) </li><li>Agriculture: 13% (2026) vs. 41% (2025) </li><li>Food and nutrition: 7% (2026) vs. 4% (2025) </li><li>Industrial and environment: 7% (2026) vs. 7% (2025) </li><li>Consumer and technology: - (2026) vs. 1% (2025) </li></ul></li><li>Revenue by Geography (2026 vs. 2025):<ul><li>U.S. customers: 66% (2026) vs. 81% (2025) </li><li>Denmark customers: 13% (2026) vs. 11% (2025) </li></ul></li></ul><h4>Operational Costs and Expenses</h4><ul><li>Cost of Other Revenue: Decreased by $1.0 million to $3.1 million in 2026 from $4.1 million in 2025, mainly due to reductions in direct equipment expenses for lab automation solutions .</li><li>Research and Development (R&amp;D) Expenses: Decreased by $21.0 million to $49.9 million in 2026 from $70.9 million in 2025 . This reduction was primarily driven by decreases in contract research expenses (-$9.4 million), personnel-related compensation and benefits (-$6.9 million), rent and facilities (-$2.6 million), depreciation and amortization (-$1.9 million), information technology expenses (-$1.8 million), and stock-based compensation expense (-$1.5 million) . These decreases were partially offset by increases in allocated overhead expenses (+$1.9 million), equipment expenses (+$0.9 million), and other operating expenses (+$0.3 million) .</li><li>General and Administrative (G&amp;A) Expenses: Decreased by $1.9 million to $37.8 million in 2026 from $39.7 million in 2025 . This was mainly due to reductions in personnel-related compensation and benefits (-$4.4 million) and other operating expenses (-$1.3 million), partially offset by an increase in rent and facilities expenses (+$3.8 million) .</li><li>Restructuring Charges: Were $0 in 2026, down from $4.5 million in 2025, as the restructuring plan initiated in 2024 was largely concluded by the fourth quarter of 2025 .</li></ul><h4>Profitability</h4><ul><li>Loss from Operations: Improved by $9.6 million, recording a loss of -$71.4 million in 2026 compared to -$81.0 million in 2025 .</li><li>Net Loss from Continuing Operations: Improved by $7.3 million, with a net loss of -$76.1 million in 2026 compared to -$83.3 million in 2025 .</li></ul><h4>Other Income (Expense)</h4><ul><li>Interest Income, Net: Decreased by $2.5 million to $3.6 million in 2026 from $6.1 million in 2025, primarily due to lower average cash balances invested .</li><li>Loss on Investments: Decreased by $2.5 million to -$1.2 million in 2026 from -$3.7 million in 2025, driven by lower impairment losses on non-marketable equity investments .</li><li>Other Expense, Net: Increased by $2.5 million to -$7.1 million in 2026 from -$4.6 million in 2025, mainly due to losses on the change in fair value of a note receivable .</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities (Continuing Operations): -$46.4 million in 2026 compared to -$42.7 million in 2025 .</li><li>Net Cash Provided by (Used in) Investing Activities: $23.1 million provided in 2026 compared to -$198.7 million used in 2025 . The 2026 figure reflects $108.2 million in maturities of marketable debt securities, partially offset by $83.2 million in purchases . The 2025 figure was primarily due to $191.2 million in purchases of marketable debt securities and $7.6 million in property and equipment purchases .</li><li>Net Cash Used in Financing Activities: -$19 thousand in 2026 compared to -$207 thousand in 2025, both primarily due to principal payments on finance leases .</li></ul><h4>Unique Metrics &amp; Discontinued Operations</h4><ul><li>Discontinued Operations (Biosecurity Business): The Biosecurity business was sold on April 3, 2026, and its financial results are presented as discontinued operations . For the three months ended March 31, 2026, it reported revenue of $6.2 million and a net loss of -$6.5 million . In 2025, it reported revenue of $10.1 million and a net loss of -$7.6 million . Net cash used in operating activities for discontinued operations was -$253 thousand in 2026, a significant decrease from -$8.8 million in 2025 .</li></ul><h4>Future Outlook and Strategy</h4>Ginkgo Bioworks Holdings, Inc. aims to make biology easier to engineer by selling cell engineering R&amp;D services and tools . The company expects R&amp;D expenses and G&amp;A expenses to remain consistent or decline in 2026, though certain investments or initiatives could lead to increases . The company anticipates that its current cash, cash equivalents, and marketable securities of $373.5 million as of March 31, 2026, will be sufficient to fund operations for at least the next 12 months, despite expenditures exceeding revenue during this period .

GINKGO BIOWORKS HOLDINGS INC C/WTS 16/09/2026 (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 19.47 M